Therapeutic response in the efficacy evaluable population (n = 114)
| Response | Placebo (n = 43) | Exisulind 200 mg (n = 38) | Exisulind 400 mg (n = 33) |
|---|---|---|---|
| *Therapeutic response = complete response+partial response. | |||
| †p = 0.8, ††p = 0.04, †††p = 0.02 compared with placebo. | |||
| Therapeutic response* | 13 (30.2%) | 13 (34.2%)† | 18 (54.6%)†† |
| Complete response | 8 (18.6%) | 4 (10.5%) | 9 (27.3%) |
| Partial response | 5 (11.6%) | 9 (23.7%) | 9 (27.3%) |
| Stable disease | 18 (41.9%) | 17 (44.7%) | 13 (39.4%) |
| Progressive disease | 12 (27.9%) | 8 (21.1%) | 2 (6.1%)††† |